Drugs

, Volume 61, Issue 2, pp 237–251

Treatment Options for Sleep Apnoea

Therapy in Practice

Abstract

Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality of life, driving accidents and probably represents a vascular disease risk factor. Currently, the most effective treatments are aimed at increasing upper airway space by either air pressure [(continuous positive airway pressure (CPAP)], upper airway surgery or oral appliances. CPAP is the main treatment modality for moderate to severe SA but noncompliance approaches 50% in clinic populations. A number of pharmacological agents have been used in SA but at this stage, none are indicated in moderate to severe SA.

References

  1. 1.
    Remmers JE, de Grott WJ, Sauerland EK, et al. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 1978; 44: 931–8PubMedGoogle Scholar
  2. 2.
    Fleetham JA. Upper airway imaging in relation to obstructive sleep apnoea. Clin Chest Med 1992; 13: 399–416PubMedGoogle Scholar
  3. 3.
    Horner RL, Innes JA, Murphey K, et al. Evidence for reflex upper airway dilator muscle activation by sudden negative airway pressure in man. J Physiol 1991; 436: 15–29PubMedGoogle Scholar
  4. 4.
    Horner RL, Innes JA, Morrell MJ, et al. The effect of sleep on reflex genioglossus muscle activation by stimuli of negative airway pressure in humans. J Physiol 1994; 476(1): 141–51PubMedGoogle Scholar
  5. 5.
    Larsson H, Carlsson-Nordlander B, Lindblad LE, et al. Temperature thresholds in the oropharynx of patients with obstructive sleep apnoea syndrome. Am Rev Respir Dis 1992; 146 (5 Pt 1): 1246–9PubMedGoogle Scholar
  6. 6.
    Bradley TD, Phillipson EA. Central sleep apnoea. Clin Chest Med 1992; 13: 493–505PubMedGoogle Scholar
  7. 7.
    Strohl KP, Redline S. Recognition of obstructive sleep apnoea. Am J Respir Crit Care Med 1996; 154: 279–89PubMedGoogle Scholar
  8. 8.
    Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–5PubMedCrossRefGoogle Scholar
  9. 9.
    Bearpark H, Elliott L, Grunstein R, et al. Snoring and sleep apnoea: a population study in Australian men. Am J Respir Crit Care Med 1995; 151: 1459–65PubMedGoogle Scholar
  10. 10.
    Grunstein R, Wilcox I, Yang TS, et al. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int JObes 1993; 17: 533–40Google Scholar
  11. 11.
    Grunstein RR, Stenlof K, Hedner J, et al. Impact of obstructive sleep apnoea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes 1995; 19: 410–8Google Scholar
  12. 12.
    Brooks LJ, Strohl KP. Size and mechanical properties of the pharynx in healthy men and women. Am Rev Respir Dis 1992; 146(6): 1394–7PubMedGoogle Scholar
  13. 13.
    Redline S, Tishler PV, Tosteson TD, et al. The familial aggregation of obstructive sleep apnoea. Am J Respir Crit Care Med 1995; 151: 682–7PubMedGoogle Scholar
  14. 14.
    Wetter DW, Young TB, Bidwell TR, et al. Smoking as a risk factor for sleep-disordered breaming. Arch Intern Med 1994; 154: 2219–24PubMedCrossRefGoogle Scholar
  15. 15.
    Grunstein RR, Ho KY, Sullivan CE. Sleep apnoea in acromegaly. Ann Intern Med 1991; 115: 527–32PubMedGoogle Scholar
  16. 16.
    Working Group on OSA and Hypertension. Obstructive sleep apnoea and blood pressure elevation: what is the relationship? Blood Press 1993; 2(3): 166–82CrossRefGoogle Scholar
  17. 17.
    Fletcher EC, Lesske J, Qian W, et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555–61PubMedCrossRefGoogle Scholar
  18. 18.
    Brooks D, Horner RL, Kozar LF, et al. Obstructive sleep apnoea as a cause of systemic hypertension: evidence from a canine model [see comments]. J Clin Invest 1997; 99(1): 106–9PubMedCrossRefGoogle Scholar
  19. 19.
    Hedner JA, Wilcox I, Laks L, et al. A specific and potent pressor effect of hypoxia in patients with sleep apnoea. Am Rev Respir Dis 1992; 146: 1240–5PubMedGoogle Scholar
  20. 20.
    Hedner J, Ejnell H, Caidahl K. Left ventricular hypertrophy independent of hypertension in patients with obstructive sleep apnoea. J Hypertens 1990; 8: 941–6PubMedCrossRefGoogle Scholar
  21. 21.
    Malone S, Liu PP, Holloway R, et al. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. Lancet 1991; 338: 1480–4PubMedCrossRefGoogle Scholar
  22. 22.
    Laks L, Lehrhaft B, Grunstein RR, et al. Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J 1995; 8: 537–41PubMedGoogle Scholar
  23. 23.
    Carlson JT, Hedner JA, Ejnell H, et al. High prevalence of hypertension in sleep apnoea patients independent of obesity. Am J Respir Crit Care Med 1994; 150(1): 72–7PubMedGoogle Scholar
  24. 24.
    Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breaming and hypertension. N Engl J Med 2000; 342(19): 1378–84PubMedCrossRefGoogle Scholar
  25. 25.
    He J, Kryger MH, Zorick FJ, et al. Mortality and apnoea index in obstructive sleep apnoea: experience in 385 male patients. Chest 1988; 94: 9–14PubMedCrossRefGoogle Scholar
  26. 26.
    Hung J, Whitford EG, Parsons RW, et al. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336: 261–4PubMedCrossRefGoogle Scholar
  27. 27.
    Palomaki H, Partinen M, Erkinjuntti T, et al. Snoring, sleep apnoea syndrome, and stroke. Neurology 1992; 42: 75–81PubMedGoogle Scholar
  28. 28.
    Köhler U, Schäfer H. Is obstructive sleep apnoea (OSA) a risk factor for myocardial infarction and cardiac arrhythmias in patients with coronary heart disease (CHD)? Sleep 1996; 19: 283–6Google Scholar
  29. 29.
    Peker Y, Hedner J, Johansson A, et al. Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnoea patients on nasal CPAP treatment. Sleep 1997; 20(8): 645–53PubMedGoogle Scholar
  30. 30.
    Quan SF, Howard BV, Iber C, et al. The sleep heart health study: design, rationale, and methods. Sleep 1997; 20(12): 1077–85PubMedGoogle Scholar
  31. 31.
    Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnoea and the risk of traffic accidents: Cooperative Group Burgos-Santander [see comments]. N Engl J Med 1999; 340(11): 847–51PubMedCrossRefGoogle Scholar
  32. 32.
    Braver HM, Block AJ, Perri MG. Treatment for snoring: combined weight loss, sleeping on side, and nasal spray. Chest 1995; 107: 1283–8PubMedCrossRefGoogle Scholar
  33. 33.
    Series F, Roy N, Marc I. Effects of sleep deprivation and sleep fragmentation on upper airway collapsibility in normal subjects. Am J Respir Crit Care Med 1994; 150(2): 481–5PubMedGoogle Scholar
  34. 34.
    Sullivan CE, Issa FG, Berthon-Jones M, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981; I: 862–5CrossRefGoogle Scholar
  35. 35.
    Grunstein RR. Sleep-related breathing disorders: 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Thorax 1995; 50(10): 1106–13Google Scholar
  36. 36.
    Ballester E, Badia JR, Hernandez L, et al. Evidence of the effectiveness of continuous positive airway pressure in the treatment of sleep apnoea/hypopnea syndrome. Am J Respir Crit Care Med 1999; 159(2): 495–501PubMedGoogle Scholar
  37. 37.
    Engleman HM, Kingshott RN, Wraith PK, et al. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnoea/Hypopnea syndrome. Am J Respir Crit Care Med 1999; 159(2): 461–7PubMedGoogle Scholar
  38. 38.
    Berthon-Jones M. Feasibility of a self-setting CPAP machine. Sleep 1993; 16: S120–S3PubMedGoogle Scholar
  39. 39.
    Meslier N, Lebrun T, Grillier-Lanoir V, et al. A French survey of 3,225 patients treated with CPAP for obstructive sleep apnoea: benefits, tolerance, compliance and quality of life. Eur Respir J 1998; 12(1): 185–92PubMedCrossRefGoogle Scholar
  40. 40.
    Sanders MH, Kern N. Obstructive sleep apnoea treated by independently adjusted inspiratory and expiratory positive airway pressures via nasal mask: physiologic and clinical implications. Chest 1990; 98: 317–24PubMedCrossRefGoogle Scholar
  41. 41.
    Schmidt-Nowara W, Lowe A, Wiegand L, et al. Oral appliances for the treatment of snoring and obstructive sleep apnoea: a review. Sleep 1995; 18(6): 501–10PubMedGoogle Scholar
  42. 42.
    Miki H, Hida W, Chonan T, et al. Effects of submental electrical stimulation during sleep on upper airway patency in patients with obstructive sleep apnoea. Am Rev Respir Dis 1989; 140: 1285–9PubMedCrossRefGoogle Scholar
  43. 43.
    Conradt R, Hochban W, Heitmann J, et al. Sleep fragmentation and daytime vigilance in patients with OSAtreated by surgical maxillomandibular advancement compared to CPAP therapy. J Sleep Res 1998; 7: 217–23PubMedCrossRefGoogle Scholar
  44. 44.
    Fujita S, Conway W, Zorick F, et al. Surgical correction of anatomic abnormalities in obstructive sleep apnoea syndrome: uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg 1981; 89: 923–34PubMedGoogle Scholar
  45. 45.
    Rodenstein DO. Assessment of uvulopalatopharyngoplasty for the treatment of sleep apnoea syndrome. Sleep 1992; 15: S56–S62PubMedGoogle Scholar
  46. 46.
    Walker EB, Frith RW, Harding DA, et al. Uvulopalatopharyngoplasty in severe idiopathic obstructive sleep apnoea syndrome. Thorax 1989; 44: 205–8PubMedCrossRefGoogle Scholar
  47. 47.
    Sher AE. Update on upper airway surgery for obstructive sleep apnoea. Curr Opin Pulm Med 1995; 1: 504–11PubMedCrossRefGoogle Scholar
  48. 48.
    Phillipson EA. Sleep apnoea: a major public health problem [editorial; comment]. N Engl J Med 1993; 328: 1271–3PubMedCrossRefGoogle Scholar
  49. 49.
    Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977; 134(2): 183–5PubMedGoogle Scholar
  50. 50.
    Brownell LG, West P, Sweatman P, et al. Protriptyline in obstructive sleep apnoea: a double-blind trial. N Engl J Med 1982; 307: 1037–42PubMedCrossRefGoogle Scholar
  51. 51.
    Clark RW, Schmidt HS, Schaal SF, et al. Sleep apnoea: treatment with protriptyline. Neurology 1979; 29: 1287–92PubMedCrossRefGoogle Scholar
  52. 52.
    Smith PL, Haponik EF, Allen RP, et al. The effects of protriptyline in sleep-disordered breaming. Am Rev Respir Dis 1983; 127: 8–13PubMedGoogle Scholar
  53. 53.
    Nykamp K, Rosenthal L, Folkerts M, et al. The effects of REM sleep deprivation on the level of sleepiness/alertness. Sleep 1998; 21(6): 609–14PubMedGoogle Scholar
  54. 54.
    Rubin AH, Alroy GG, Peled R, et al. Preliminary clinical experience with imipramine HCl in the treatment of sleep apnoea syndrome. Eur Neurol 1986; 25: 81–5PubMedCrossRefGoogle Scholar
  55. 55.
    Meyer Madaus H, Haug HJ, Kessler C. Imipramine in sleep apnoea syndrome [in German]. Dtsch Med Wochenschr 1991; 116(45): 1734–5PubMedGoogle Scholar
  56. 56.
    Schmidt HS. L-tryptophan in the treatment of impaired respiration in sleep. Bull Eur Physiopathol Respir 1983; 19: 625–9PubMedGoogle Scholar
  57. 57.
    Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnoea to fluoxetine and protriptyline. Chest 1991; 100: 416–21PubMedCrossRefGoogle Scholar
  58. 58.
    Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breaming during sleep and daytime symptoms in obstructive sleep apnoea. Sleep 1999; 22(1): 61–7PubMedGoogle Scholar
  59. 59.
    Rose D, Khater-Boidin J, Toussaint P, et al. Central effects of 5-HT on respiratory and hypoglossal activities in the adult cat. Respir Physiol 1995; 101(1): 59–69PubMedCrossRefGoogle Scholar
  60. 60.
    Veasey SC, Panckeri KA, Hoffman EA, et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med 1996; 153(2): 776–86PubMedGoogle Scholar
  61. 61.
    Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 1998; 84(3): 1055–62PubMedGoogle Scholar
  62. 62.
    Cistulli PA, Barnes DJ, Grunstein RR, et al. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 1994; 49(7): 699–702PubMedCrossRefGoogle Scholar
  63. 63.
    Stewart DA, Grunstein RR, Berthon-Jones M, et al. Androgen blockade does not affect sleep-disordered breaming or chemosensitivity in men with obstructive sleep apnoea. Am Rev Respir Dis 1992; 146: 1389–93PubMedGoogle Scholar
  64. 64.
    Cook WR, Benich JJ, Wooten SA. Indices of severity of obstructive sleep apnoea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989; 96: 262–6PubMedCrossRefGoogle Scholar
  65. 65.
    Rajagopal KR, Abbrecht PH, Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnoea. Chest 1986; 90: 815–21PubMedCrossRefGoogle Scholar
  66. 66.
    Bayliss DA, Millhorn DE, Gallman EA, et al. Progesterone stimulates respiration through a central nervous system steroid receptor-mediated mechanism in cat. Proc Natl Acad Sci U S A 1987; 84(21): 7788–92PubMedCrossRefGoogle Scholar
  67. 67.
    Hannhart B, Pickett CK, Moore LG. Effects of estrogen and progesterone on carotid body neural output responsiveness to hypoxia. J Appl Physiol 1990; 68(5): 1909–16PubMedGoogle Scholar
  68. 68.
    Sutton Jr FD, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83: 476–9PubMedGoogle Scholar
  69. 69.
    Saaresranta T, Polo-Kantola P, Irjala K, et al. Respiratory insufficiency in postmenopausal women: sustained improvement of gas exchange with short-term medroxyprogesterone acetate. Chest 1999; 15: 1581–7CrossRefGoogle Scholar
  70. 70.
    Grieger E, Schneider H, Weichler U, et al. Therapy control of theophylline evening dosage in patients with sleep-related respiratory disorders: follow-up study [in German]. Pneumologie 1993; 47 Suppl. 1: 166–9PubMedGoogle Scholar
  71. 71.
    Kempf P, Mossinger B, Muller B, et al. Comparative studies on the effect of nasal CPAP, theophylline and oxygen in patients with sleep apnea syndrome [in German]. Pneumologie 1991; 45 Suppl. 1: 279–82PubMedGoogle Scholar
  72. 72.
    Guilleminault C, Hayes B. Naloxone, theophylline, bromocriptine, and obstructive sleep apnoea: negative results. Bull Eur Physiopathol Respir 1983; 19: 632–4PubMedGoogle Scholar
  73. 73.
    Espinoza H, Antic R, Thornton AT, et al. The effects of aminophylline on sleep and sleep-disordered breaming in patients with obstructive sleep apnoea syndrome. Am Rev Respir Dis 1987; 136: 80–4PubMedCrossRefGoogle Scholar
  74. 74.
    Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnoea: a double-blind evaluation. Chest 1992; 101(3): 753–7PubMedCrossRefGoogle Scholar
  75. 75.
    Roehrs T, Merlotti L, Halpin D, et al. Effects of theophylline on nocturnal sleep and daytime sleepiness/alertness. Chest 1995; 108(2): 382–7PubMedCrossRefGoogle Scholar
  76. 76.
    Schwartz AR, Rowley JA, O’Donnell C, et al. Effect of hypertension on upper airway function and sleep. J Sleep Res 1995; 4 Suppl. 1: 83–8PubMedCrossRefGoogle Scholar
  77. 77.
    Wilson CR, Manchanda S, Crabtree D, et al. An induced blood pressure rise does not alter upper airway resistance in sleeping humans. J Appl Physiol 1998; 84(1): 269–76PubMedGoogle Scholar
  78. 78.
    Carley DW, Trbovic SM, Radulovacki M. Hydralazine reduces elevated sleep apnoea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats. Sleep 1996; 19(5): 363–6PubMedGoogle Scholar
  79. 79.
    Weichler U, Herres Mayer B, Mayer J, et al. Influence of anti-hypertensive drug therapy on sleep pattern and sleep apnoea activity. Cardiology 1991; 78: 124–30PubMedCrossRefGoogle Scholar
  80. 80.
    Issa FG. Effect of clonidine in obstructive sleep apnoea. Am Rev Respir Dis 1992; 145: 435–9PubMedGoogle Scholar
  81. 81.
    Kantola I, Rauhala E, Erkinjuntti M, et al. Sleep disturbances in hypertension: a double-blind study between isradipine and metoprolol. J Cardiovasc Pharmacol 1991; 18 Suppl. 3: S41–S5PubMedGoogle Scholar
  82. 82.
    Heitmann J, Grote L, Knaack L, et al. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnoea [in process citation]. Eur J Clin Pharmacol 1998; 54(9–10): 691–6PubMedCrossRefGoogle Scholar
  83. 83.
    Gold AR, Schwartz AR, Bleecker ER, et al. The effect of chronic nocturnal oxygen administration upon sleep apnoea. Am Rev Respir Dis 1986; 134: 925–9PubMedGoogle Scholar
  84. 84.
    Hudgel DW, Hendricks C, Dadley A. Alteration in obstructive apnoea pattern induced by changes in oxygen-and carbondioxide-inspired concentrations. Am Rev Respir Dis 1988; 138: 16–9PubMedCrossRefGoogle Scholar
  85. 85.
    Gothe B, Strohl KP, Levin S, et al. Nicotine: a different approach to treatment of obstructive sleep apnoea. Chest 1985; 87: 11–7PubMedCrossRefGoogle Scholar
  86. 86.
    Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breaming in nonsmokers. Am J Respir Crit Care Med 1994; 150(2): 469–74PubMedGoogle Scholar
  87. 87.
    Schönhofer B, Köhler D. Benzodiazepine receptor antagonist (flumazenil) does not affect sleep-related breaming disorders. Eur Respir J 1996; 9: 1816–20PubMedCrossRefGoogle Scholar
  88. 88.
    Hedner J, Grunstein R, Eriksson B, et al. A double-blind, randomized trial of sabeluzole —a putative glutamate antagonist —in obstructive sleep apnea. Sleep 1996; 19(4): 287–9PubMedGoogle Scholar
  89. 89.
    Arnulf I, Homeyer P, Garma L, et al. Modafinil in obstructive sleep apnoea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997; 64(2): 159–61PubMedCrossRefGoogle Scholar
  90. 90.
    Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnoea in patients with acromegaly. Ann Intern Med 1994; 121: 478–83PubMedGoogle Scholar
  91. 91.
    Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnoea in hypothyroidism. Ann Intern Med 1984; 101: 491–4PubMedGoogle Scholar
  92. 92.
    Orr WC, Males JI, Imes NK. Myxedema and obstructive sleep apnoea. Am J Med 1981; 70: 1061–6PubMedCrossRefGoogle Scholar
  93. 93.
    Kapur VK, Koepsell TD, deMaube J, et al. Association of hypothyroidism and obstructive sleep apnoea. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1379–83PubMedGoogle Scholar
  94. 94.
    Grunstein RR, Sullivan CE. Sleep apnoea and hypothyroidism: mechanisms and management. Am J Med 1988; 85: 775–9PubMedCrossRefGoogle Scholar
  95. 95.
    White DP, Zwillich CW, Pickett CK, et al. Central sleep apnoea: improvement with acetazolamide therapy. Arch Intern Med 1982; 142: 1816–9PubMedCrossRefGoogle Scholar
  96. 96.
    Debacker WA, Verbraecken J, Willemen M, et al. Central apnoea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 1995; 151: 87–91PubMedGoogle Scholar
  97. 97.
    Verbraecken J, Willemen M, De Cock W, et al. Central sleep apnoea after interrupting long term acetazolamide therapy. Respir Physiol 1998; 112(1): 59–70PubMedCrossRefGoogle Scholar
  98. 98.
    Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure [see comments]. N Engl J Med 1996; 335(8): 562–7PubMedCrossRefGoogle Scholar
  99. 99.
    Naughton MT, Bradley TD. Sleep apnoea in congestive heart failure. Clin Chest Med 1998; 19(1): 99–113PubMedCrossRefGoogle Scholar
  100. 100.
    Bonnet MH, Dexter JR, Arand DL. The effect of triazolam on arousal and respiration in central sleep apnoea patients. Sleep 1990; 13: 31–41PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Ronald R. Grunstein
    • 1
  • Jan Hedner
    • 2
  • Ludger Grote
    • 2
  1. 1.Centre for Respiratory Failure and Sleep Disorders, Ward E9Royal Prince Alfred Hospital and University of Sydney, and Sleep Disorder Service, St Vincent’s ClinicCamperdownAustralia
  2. 2.Department of Clinical PharmacologySahlgrens HospitalGothenburgSweden

Personalised recommendations